Skip to content

Peptide library / Hormones & metabolism / Pegvisomant

FDA-approvedHormones & metabolism

Pegvisomant

A growth hormone receptor blocker for acromegaly.

Body system
Hormones & metabolism
Status
FDA-approved
Strongest evidence
FDA approved
Also known as
Somavert

Effects studied or claimed

What it is used or promoted for, and where each effect has actually been seen

  • AcromegalyFDA approved

How it is thought to work

Pegvisomant is a modified growth hormone that binds the receptor without activating it, lowering IGF-1.

What the evidence shows

Normalizes IGF-1 in most patients in trials and long-term registries.

Safety and unknowns

Liver enzyme rises and injection site reactions. Tumor size should be monitored.

Regulatory status

FDA-approved as Somavert in 2003.

Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.

Sources

More in Hormones & metabolism

Protirelin

FDA-approved
Hormones & metabolism · TRH, Thyrel

Thyrotropin-releasing hormone, a three amino acid hormone from the hypothalamus.

EvidenceFDA approved

Sermorelin

Wellness and performance
Hormones & metabolism · Geref

A growth hormone-releasing hormone fragment once approved for children and now compounded for adults.

EvidenceSmall human studies

Pasireotide

FDA-approved
Hormones & metabolism · Signifor

A multi-receptor somatostatin analog for Cushing disease and acromegaly.

EvidenceFDA approved
← PasireotideAll peptidesProtirelin →

General information, not medical advice. Do not buy or inject unregulated peptides.